CR20250172A - Composiciones y métodos para la modulación de la actividad de macrófagos - Google Patents

Composiciones y métodos para la modulación de la actividad de macrófagos

Info

Publication number
CR20250172A
CR20250172A CR20250172A CR20250172A CR20250172A CR 20250172 A CR20250172 A CR 20250172A CR 20250172 A CR20250172 A CR 20250172A CR 20250172 A CR20250172 A CR 20250172A CR 20250172 A CR20250172 A CR 20250172A
Authority
CR
Costa Rica
Prior art keywords
modulation
compositions
methods
macrophage activity
human
Prior art date
Application number
CR20250172A
Other languages
English (en)
Spanish (es)
Inventor
Carola Ries
Krzysztof B Wicher
Luca Cassetta
Stephen Myatt
Original Assignee
Macomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macomics Ltd filed Critical Macomics Ltd
Priority claimed from PCT/GB2023/050592 external-priority patent/WO2023170434A1/en
Publication of CR20250172A publication Critical patent/CR20250172A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CR20250172A 2022-10-04 2023-03-13 Composiciones y métodos para la modulación de la actividad de macrófagos CR20250172A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2214614.6A GB202214614D0 (en) 2022-10-04 2022-10-04 Compositions and methods for modulation of macrophage
PCT/GB2023/050592 WO2023170434A1 (en) 2022-03-11 2023-03-13 Compositions and methods for modulation of macrophage activity

Publications (1)

Publication Number Publication Date
CR20250172A true CR20250172A (es) 2025-09-04

Family

ID=84000149

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250172A CR20250172A (es) 2022-10-04 2023-03-13 Composiciones y métodos para la modulación de la actividad de macrófagos

Country Status (8)

Country Link
JP (1) JP2025535192A (https=)
KR (1) KR20250096720A (https=)
CN (1) CN120435496A (https=)
AU (1) AU2023232991A1 (https=)
CR (1) CR20250172A (https=)
GB (1) GB202214614D0 (https=)
IL (1) IL319958A (https=)
MX (1) MX2025003929A (https=)

Also Published As

Publication number Publication date
JP2025535192A (ja) 2025-10-22
MX2025003929A (es) 2025-05-02
IL319958A (en) 2025-05-01
AU2023232991A1 (en) 2025-04-10
CN120435496A (zh) 2025-08-05
KR20250096720A (ko) 2025-06-27
GB202214614D0 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
CO2020015383A2 (es) Anticuerpos dirigidos contra il-11
CO2019010023A2 (es) Compuestos de dinucleótidos cíclicos modificados
EP3856226C0 (en) CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATION
EP3747022A4 (en) WOUND IMAGING AND ANALYSIS
EP3935742A4 (en) Compression and decompression of downlink channel estimates
MX2020013468A (es) Anticuerpos il-11ra.
EP4428232A4 (en) Isolated Cas13 protein and its use
JP1745670S (ja) カニューレ
CR20250172A (es) Composiciones y métodos para la modulación de la actividad de macrófagos
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.
EP4512825A4 (en) COLLAGEN AND ITS USE
CL2021003071A1 (es) Activación de explosivos en agujeros
EP4036219C0 (en) BACTERIAL STRAIN AND ITS USE
EP4149496A4 (en) Sars-cov-2-specific t cells
EP4364659A4 (en) APPLICATOR FOR TRANSCUTANEOUS SENSOR AND APPLICATOR ASSEMBLY
MX2015008997A (es) Moleculas pequeñas que promueven la regeneracion de la piel.
EP4299593A4 (en) CLDN18.2 ANTIGEN-BINDING PROTEIN AND ITS USE
ZA202204386B (en) Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
WO2020046769A8 (en) Hematostick/hematodart
MX2023003785A (es) Inhibidores de imidazopiperazina de proteinas de activacion de transcripcion.
EP3981379C0 (en) NANOEMULSION COMPOSITION FOR SKIN CARE APPLICATION
EP4368103A4 (en) TRANSCUTANEOUS SENSOR APPLICATOR AND APPLICATOR ASSEMBLY
EP4153982A4 (en) Sars-cov-2 (covid-19) antibody test on saliva and blood using efirm technology
EP3856234A4 (en) MODULATION OF GRANZYME K ACTIVITY IN THE TREATMENT OF SKIN CONDITIONS
EP4344625A4 (en) Applicator for transcutaneous sensor, and applicator assembly